Publications by authors named "Gaia Bedeschi"
Article Synopsis
- Kidney transplant maintenance therapy usually includes calcineurin inhibitors like tacrolimus or cyclosporine, often paired with mycophenolate or mTOR inhibitors, and sometimes corticosteroids.
- A study from Italy analyzed the risk and benefits of various immunosuppressive regimens in kidney transplant patients between 2009 and 2019, focusing on the safety and effectiveness of tacrolimus versus cyclosporine and comparing mTORi with mycophenolate.
- Results indicated that tacrolimus therapy had lower risks of graft rejection and severe infections than cyclosporine, despite a higher incidence of diabetes; mTORi showed similar efficacy to mycophenolate, suggesting it could be a viable alternative.
Background: Very scanty evidence is available on factors influencing the choice of immunosuppressive drug therapy after kidney transplantation.
Methods: An Italian multiregional real-world study was conducted integrating national transplant information system and claims data. All patients undergoing kidney transplantation for the first time during 2009-2019 (incident patients) were considered.
[Not Available].
Recenti Prog Med
September 2023
Background: In immunosuppression after transplantation, several multi-drug approaches are used, involving calcineurin inhibitors (), antimetabolites (), mammalian target of rapamycin inhibitors (), and corticosteroids. However, data on immunosuppressive therapy by organ and its space-time variability are lacking.
Methods: An Italian multicentre observational cohort study was conducted using health information systems.
An Italian multicentre distributed data research network to study the use, effectiveness, and safety of immunosuppressive drugs in transplant patients: Framework and perspectives of the CESIT project.
Front Pharmacol
September 2022
The goal of post-transplant immunosuppressive drug therapy is to prevent organ rejection while minimizing drug toxicities. In clinical practice, a multidrug approach is commonly used and involves drugs with different mechanisms of action, including calcineurin inhibitors (CNI) (tacrolimus or cyclosporine), antimetabolite (antimet) (mycophenolate or azathioprine), inhibitors of mechanistic target of rapamycin (mTOR) (sirolimus or everolimus), and/or steroids. Although evidence based on several randomized clinical trials is available, the optimal immunosuppressive therapy has not been established and may vary among organ transplant settings.
View Article and Find Full Text PDF